Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2010

01.12.2010 | Gastrointestinal Oncology

The Fibroblast Growth Factor Receptor-4 Arg388 Allele is Associated with Gastric Cancer Progression

verfasst von: Yanwei Ye, MD, Yingqiang Shi, MD, Ye Zhou, MD, Chunyan Du, MD, Chunmeng Wang, MD, Heqin Zhan, PhD, Biqiang Zheng, PhD, Xi Cao, MD, Meng-hong Sun, MD, Hong Fu, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism, located in the FGFR4 gene exon 9, was reported to be associated with malignant tumors prognosis; however, there has been no relevant research for gastric cancer. The purpose of this study was to investigate the clinical significance of FGFR4 Gly388Arg polymorphism as well as the mRNA expression of FGFR4 in patients with gastric cancer.

Methods

The mRNA expression of FGFR4 in 103 gastric cancer tissues and corresponding normal tissues were measured by reverse transcription polymerase chain reaction (PCR) and real-time quantitative PCR. PCR-restriction fragment length polymorphism analysis was performed to detect the FGFR4 Gly388Arg in 103 gastric cancer tissues.

Results

In 57.3% of patients, homozygous or heterozygous Arg388 allele was present. FGFR4 expressions in mRNA levels were higher in gastric cancer tissues compared with those in relevant normal tissues. However, there is no significantly statistical difference compared with mRNA expression of FGFR4 in different genotypes. Associations between FGFR4 Gly388Arg polymorphism and overall survival exist in patients with gastric cancer (P = 0.046).The FGFR4 Arg allele (hazard risk (HR), 2.324; 95% confidence interval (CI), 1.054–4.125; P = 0.037) and TNM stage (HR, 5.516; 95% CI 3.658–7.409; P = 0.005) were independent prognostic factors in patients with gastric cancer.

Conclusions

Based on this study, FGFR4 Arg388 genotype—a marker for gastric cancer progression—may predict prognosis of gastric cancer.
Literatur
1.
Zurück zum Zitat Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMed Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMed
2.
Zurück zum Zitat Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115–65.CrossRefPubMed Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115–65.CrossRefPubMed
3.
Zurück zum Zitat Ozen M, Giri D, Ropiquet F, et al. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst (Bethesda). 2001;93:1783–90. Ozen M, Giri D, Ropiquet F, et al. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst (Bethesda). 2001;93:1783–90.
4.
Zurück zum Zitat Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139–49.CrossRefPubMed Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139–49.CrossRefPubMed
5.
Zurück zum Zitat Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res. 2004;10:6169–78.CrossRefPubMed Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res. 2004;10:6169–78.CrossRefPubMed
6.
Zurück zum Zitat Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002;62:840–7.PubMed Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002;62:840–7.PubMed
7.
Zurück zum Zitat Nakamura N, Iijima T, Mase K, et al. Phenotypic differences of proliferating fibroblasts in the stroma of lung adenocarcinoma and normal bronchus tissue. Cancer Sci. 2004;95:226–32.CrossRefPubMed Nakamura N, Iijima T, Mase K, et al. Phenotypic differences of proliferating fibroblasts in the stroma of lung adenocarcinoma and normal bronchus tissue. Cancer Sci. 2004;95:226–32.CrossRefPubMed
8.
Zurück zum Zitat Kan M, Wu X, Wang F, et al. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem. 1999;274:15947–52.CrossRefPubMed Kan M, Wu X, Wang F, et al. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem. 1999;274:15947–52.CrossRefPubMed
9.
Zurück zum Zitat Lin BC, Wang M, Blackmore C, et al. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem. 2007;282:27277–84.CrossRefPubMed Lin BC, Wang M, Blackmore C, et al. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem. 2007;282:27277–84.CrossRefPubMed
10.
Zurück zum Zitat Leung HY, Gullick WJ, Lemoine NR. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer. 1994;59:667–75.CrossRefPubMed Leung HY, Gullick WJ, Lemoine NR. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer. 1994;59:667–75.CrossRefPubMed
11.
Zurück zum Zitat Takahashi A, Sasaki H, Kim SJ, et al. Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem Biophys Res Commun. 1999;257:855–9.CrossRefPubMed Takahashi A, Sasaki H, Kim SJ, et al. Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem Biophys Res Commun. 1999;257:855–9.CrossRefPubMed
12.
Zurück zum Zitat Thussbas C, Nahrig J, Streit S, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol. 2006;24:3747–55.CrossRefPubMed Thussbas C, Nahrig J, Streit S, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol. 2006;24:3747–55.CrossRefPubMed
13.
Zurück zum Zitat Spinola M, Leoni V, Pignatiello C, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol. 2005;23:7307–11.CrossRefPubMed Spinola M, Leoni V, Pignatiello C, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol. 2005;23:7307–11.CrossRefPubMed
14.
Zurück zum Zitat Streit S, Bange J, Fichtner A, et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer. 2004;111:213–7.CrossRefPubMed Streit S, Bange J, Fichtner A, et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer. 2004;111:213–7.CrossRefPubMed
15.
Zurück zum Zitat Morimoto Y, Ozaki T, Ouchida M, et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer. 2003;98:2245–50.CrossRefPubMed Morimoto Y, Ozaki T, Ouchida M, et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer. 2003;98:2245–50.CrossRefPubMed
16.
Zurück zum Zitat Ma Z, Tsuchiya N, Yuasa T, et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer. 2008;123:2574–9.CrossRefPubMed Ma Z, Tsuchiya N, Yuasa T, et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer. 2008;123:2574–9.CrossRefPubMed
17.
Zurück zum Zitat Falvella FS, Frullanti E, Galvan A, et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer. 2009;124:2880–5.CrossRefPubMed Falvella FS, Frullanti E, Galvan A, et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer. 2009;124:2880–5.CrossRefPubMed
18.
Zurück zum Zitat Tanuma J, Izumo T, Hirano M, et al. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. Oncol Rep. 2010;23:739–44.PubMed Tanuma J, Izumo T, Hirano M, et al. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. Oncol Rep. 2010;23:739–44.PubMed
19.
Zurück zum Zitat Matakidou A, El Galta R, Rudd MF, et al. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer. 2007;96:1904–7.CrossRefPubMed Matakidou A, El Galta R, Rudd MF, et al. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer. 2007;96:1904–7.CrossRefPubMed
20.
Zurück zum Zitat Yang YC, Lu ML, Rao JY, et al. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer. 2006;95:1455–8.CrossRefPubMed Yang YC, Lu ML, Rao JY, et al. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer. 2006;95:1455–8.CrossRefPubMed
21.
Zurück zum Zitat Ho CK, Anwar S, Nanda J, et al. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men. Prostate Cancer Prostatic Dis. 2010;13:94–6.CrossRefPubMed Ho CK, Anwar S, Nanda J, et al. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men. Prostate Cancer Prostatic Dis. 2010;13:94–6.CrossRefPubMed
22.
Zurück zum Zitat Naidu R, Har YC, Taib NA. Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development. Oncol Res. 2009;18:65–71.CrossRefPubMed Naidu R, Har YC, Taib NA. Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development. Oncol Res. 2009;18:65–71.CrossRefPubMed
23.
Zurück zum Zitat Ho HK, Pok S, Streit S, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol. 2009;50:118–27.CrossRefPubMed Ho HK, Pok S, Streit S, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol. 2009;50:118–27.CrossRefPubMed
Metadaten
Titel
The Fibroblast Growth Factor Receptor-4 Arg388 Allele is Associated with Gastric Cancer Progression
verfasst von
Yanwei Ye, MD
Yingqiang Shi, MD
Ye Zhou, MD
Chunyan Du, MD
Chunmeng Wang, MD
Heqin Zhan, PhD
Biqiang Zheng, PhD
Xi Cao, MD
Meng-hong Sun, MD
Hong Fu, MD
Publikationsdatum
01.12.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1323-6

Weitere Artikel der Ausgabe 12/2010

Annals of Surgical Oncology 12/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.